chasesurvival

Novartis and Molecular Partners Report Positive Data From COVID-19 Antiviral Trial. Molecular Partners had already received an upfront payment of 60 million francs including equity. Pin On Molecular Biology January 10 2022 0117 ET Source. . The company is developing a new class of potent specific and versatile small-protein therapies called DARPins with potential clinical applications in a range of disease areas including oncology immuno-oncology ophthalmology and immunology. Novartis has the scope and resources to get ensovibep marketed quickly and broadly. The company has compounds in various stages of clinical and preclinical development with a focus on oncology. Molecular Partners and Novartis announced that the initial part of a phase 2 clinical trial evaluating intravenous dosing of that drug ensovibep met its. Molecular Partners had already received an upfront payment of 60 million francs including equity. With the dec...